ChIPAb+ Acetyl-Histone H3 (Lys27) - ChIP Validated Antibody and Primer Set
All ChIPAb+ antibodies are individually validated for chromatin precipitation, every lot, every time. Each ChIPAb+ antibody set includes control primers (tested every lot by qPCR) to biologically validate your IP results in a locus-specific context. The qPCR protocol and primer sequences are provided, allowing researchers to validate ChIP protocols when using our antibody in their chromatin context. Each set also includes a negative control antibody to ensure specificity of the ChIP reaction. The ChIPAb+ Acetyl-Histone H3 (Lys27) set includes the Anti-acetyl-Histone H3 (Lys27) antibody, a negative control antibody (purified Mouse IgG), and qPCR primers which amplify a 178 bp region within the promoter of the human RPL10 gene. The acetyl-histone H3 (Lys27) and negative control antibodies are supplied in a scalable "per ChIP" reaction size and can be used to functionally validate the precipitation of acetyl-histone H3 (Lys27)-associated chromatin.
Product Details
- Cat. No.
- 17-683
- Type
- Primary Antibody
- Clonality
- Monoclonal
- Host
- Mouse
The supplier does not provide quotations for this antibody through SelectScience. You can search for similar antibodies in our Antibody Directory.
Reviews
Antibody with high quality.
ChIP and ChIP-seq
I always achieve reproducible results for ChIP experiments with this antibody. It is reliable, and easy to use. It contains primer set as negative control and positive control.
Review Date: 4 Dec 2018 | Merck KGaA, Darmstadt, Germany
Applications
- Chromatin Immunoprecipitation (ChIP)
- Western Blotting (WB)
Antibody Overview
About the company
Merck KGaA, Darmstadt, Germany
Merck, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck generated sales of €16.2 billion in 66 countries.